Skip to main content
RYVU Therapeutics S.A. logo

RYVU Therapeutics S.A. — Investor Relations & Filings

Ticker · RVU ISIN · PLSELVT00013 LEI · 2594003WO9Q9HHAFL031 WAR Professional, scientific and technical activities
Open in API
Filings indexed 811 across all filing types
Latest filing 2026-05-21 Interim / Quarterly Rep…
Country PL Poland
Listing WAR RVU

About RYVU Therapeutics S.A.

https://ryvu.com/

Ryvu Therapeutics is a clinical-stage drug discovery and development company specializing in novel small molecule therapies for oncology. The company's research focuses on emerging biological targets and pathways, including kinase inhibition, synthetic lethality, and immuno-oncology, to develop precise cancer treatments. Its pipeline features several candidates in various stages of development. Key clinical-stage assets include Romaciclib (RVU120), a selective CDK8/19 kinase inhibitor for treating hematologic malignancies like acute myeloid leukemia (AML) and myelofibrosis, and Dapolsertib (MEN1703), a PIM/FLT3 inhibitor. The company also advances preclinical programs, such as an MTA-cooperative PRMT5 inhibitor for solid tumors with MTAP deletion.

Recent filings

Filing Released Lang Actions
Sprawozdanie Zarządu z dzialalności_Q1_2026_ENG
Interim / Quarterly Report Classification · 95% confidence The document is titled “Q1 2026 Report” and contains condensed interim financial statements prepared under IAS 34, including balance sheet, income statement, cash flows, management commentary on quarterly results, asset structure, and outlook. This is a comprehensive financial report for a period shorter than a fiscal year (first quarter), matching the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-05-21 English
Sprawozdanie Zarządu z dzialalności_Q1_2026_PL
Interim / Quarterly Report Classification · 95% confidence The document is a quarterly financial report (“Raport Q1 2026”) by Ryvu Therapeutics S.A., containing detailed interim financial statements (balance sheet, income statement, cash flows), management commentary on results, assets and liabilities structure, and substantive analysis for the period 1 January – 31 March 2026. This meets the criteria for an Interim / Quarterly Report (IR), as it provides comprehensive financial data and commentary for a period shorter than a full fiscal year. Q1 2026
2026-05-21 Polish
Sprawozdanie Finansowe_Q1_2026_PL
Interim / Quarterly Report Classification · 92% confidence The document is titled “Śródroczne skrócone sprawozdanie finansowe” and covers the period 01.01.2026–31.03.2026 under IFRS standard 34. It includes condensed financial statements (income, balance sheet, cash flow, equity changes) and explanatory notes – all indicative of an actual interim/quarterly report rather than a mere announcement. Therefore, it fits the Interim / Quarterly Report category. Q1 2026
2026-05-21 Polish
Sprawozdanie Finansowe_Q1_2026_ENG
Interim / Quarterly Report Classification · 97% confidence The document is titled “Condensed interim financial statements” for the period 1 January 2026 to 31 March 2026 and prepared under IAS 34. It includes full interim statements of comprehensive income, financial position, changes in equity, cash flows, and accompanying notes for a quarter. This matches the definition of an Interim/Quarterly Report (IR). Q1 2026
2026-05-21 English
Aktualizacja priorytetów rozwoju romacyklibu / Romaciclib development priorities update - Content (EN)
Regulatory Filings Classification · 88% confidence The document is a Current Report (“ESPI”) by the management board detailing development and resource priorities for a clinical program. It does not contain financial statements, new fundraising, or dividend/share transactions. It is not an investor presentation or earnings release but a general regulatory announcement of material corporate developments. Under our taxonomy, this falls into the fallback category “Regulatory Filings (RNS).”
2026-05-20 English
Aktualizacja priorytetów rozwoju romacyklibu / Romaciclib development priorities update - Content (PL)
Management Reports Classification · 75% confidence The document is a corporate bulletin by the Management Board updating clinical development priorities, resource allocation and expected financial outlook for 2026–2027. It contains management discussion of business trends and outlook rather than financial statements, fundraising announcements, or board changes. This fits the “Management Reports” category (MDA).
2026-05-20 Polish

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.